A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Czechia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Smetanova 830, 565 01 Chocen, Czechia
Neurohk s.r.o. in Chocen, Czechia specialises in clinical trials of conditions such as Dementia Alzheimer's type, Migraine, Dementia of the Alzheimer's type with delusions, Migraine without aura, and other specialisations. This site conducts important research.
Neurohk s.r.o. is conducting studies that target pain and movement disorders, aiming to improve symptom relief and functional outcomes for patients with chronic conditions.
The research focuses on evaluating new therapeutic approaches to reduce pain intensity and enhance quality of life for individuals whose standard treatments have been insufficient.
The site’s neurology program investigates treatments for progressive neurological disorders, seeking to slow disease progression and preserve motor and cognitive function.
By testing innovative agents, researchers aim to provide safer, more effective options for patients living with these chronic nervous‑system diseases.
Clinical work at Neurohk s.r.o. addresses neuropsychiatric symptoms that significantly impact daily living, with a focus on developing therapies that lessen severe behavioral disturbances.
The trials evaluate safety and efficacy of novel compounds to improve behavioral outcomes and reduce caregiver burden in affected individuals.
Research into core psychological symptoms accompanies the site’s broader neuro‑psychiatric agenda, aiming to refine treatment strategies for complex mental presentations.
Findings from these studies are intended to guide clinicians toward more precise, patient‑centered interventions for challenging psychological phenomena.
Clinical trials currently enrolling participants at this site.
CzechiaOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
CzechiaA study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease
CzechiaStudy of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation
CzechiaStudy of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks
CzechiaStudy on IPN10200 for Treating Cervical Dystonia in Adults
CzechiaLong‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis
CzechiaA Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis
CzechiaA Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis
CzechiaA Study of Fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.
CzechiaStudy on ITI-1284 for Treating Agitation in Alzheimer's Patients
CzechiaStudy on ITI-1284 for Treating Psychosis in Alzheimer's Patients
CzechiaMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.